

Amendment history for PP6298217

Granted 25 April 2022

- Addition of minipump implantation to protocol 7

Granted 28 September 2022

- Addition of a new objective (5) and protocol (8) for the investigation of the biodistribution of test agents
- Addition of a new protocol (9) for the investigation of the tolerability of test agents dosed continuously

Granted 9 March 2023

- Addition of a new protocol (10) for the delivery of test agents directly to the brain
- Addition of collection of tissues under terminal anaesthesia to protocol 7.
- Increase in the maximum number of mice on protocol 1.

Granted 16 June 2023

- Increase in the maximum number of rats on protocol 7.

Granted 8 November 2023

- Inclusion of liver failure as a new disease area
- Addition of a new protocol (11) for portal vein test agent delivery.
- Clarification of test agent wording

Granted 7 June 2024

- Clarification of wording for weight loss humane endpoints (protocols 2, 3, 5, 8, 9, 10, 11)
- Clarification for monitoring in tolerability studies (Protocol 6, step 1)
- Addition of standard NSG mice adverse effects wording (Protocols 5, 6, 7, 8, 11)

Granted 31 October 2024

- Inclusion of a new objective (6) and protocol (12) for target engagement studies
- Inclusion of a new objective (7) and protocol (13) to determine suitable human donors for immune cells and to test the effect on biomarkers of test agents in humanised mice
- Addition of AB code to intraperitoneal dosing (protocol 7)
- Addition of intramuscular dosing (Protocols 6 & 7)

Granted 31 October 2025

- Inclusion of a new method for administration of test agents to the liver (protocol 11)
- Inclusion of a new protocol (14) for the administration of test agents to the kidney capsule.
- Inclusion of imaging step to protocols 10, 11 & 14.
- Inclusion of subcutaneous fat pad injection to protocols 7 & 8.

Granted 18 March 2025

- Inclusion of new adverse effects for direct brain injection

Granted 15 May 2025

- Inclusion of aged mice on protocols 1, 2, 7 & 8

Granted 28 July 2025

- Addition of infectious diseases as a new disease area
- Clarification of weight loss endpoints on protocol 8